Sandoz and Pear Therapeutics Announce US Launch of reSET-O™ to Help Treat Opioid Use Disorder

Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). reSET-O, cleared by the US Food and Drug Administration (FDA) in December, is immediately available.